CSIMarket
 
Centessa Pharmaceuticals Plc  (CNTA)
Other Ticker:  
 
 
Price: $10.7500 $0.28 2.674%
Day's High: $10.94 Week Perf: 10.26 %
Day's Low: $ 10.30 30 Day Perf: 5.6 %
Volume (M): 217 52 Wk High: $ 11.95
Volume (M$): $ 2,328 52 Wk Avg: $6.64
Open: $10.48 52 Wk Low: $3.38



 Market Capitalization (Millions $) 1,039
 Shares Outstanding (Millions) 97
 Employees 350
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -157
 Cash Flow (TTM) (Millions $) -222
 Capital Exp. (TTM) (Millions $) 0

Centessa Pharmaceuticals Plc
Centessa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company that is focused on developing transformative medicines for patients who have unmet medical needs. They are committed to bridging the gap between science and patients, and they are working hard to develop therapies that can change the course of disease.

The company was founded in 2020 and is headquartered in Cambridge, Massachusetts. Centessa is a publicly traded company on the NASDAQ stock exchange and is traded under the symbol CNTA. They have a diverse pipeline of drug candidates that are focused on a variety of therapeutic indications, including immuno-oncology, hematology, and genetic diseases.

One of the hallmarks of Centessa is its unique business model, which is based on a "hub-and-spoke" approach. They have acquired a number of smaller biotech companies and are operating them as individual subsidiaries, each with its own research and development team. This allows Centessa to harness the power of multiple organizations and bring together a range of expertise and resources.

The company's pipeline includes a number of promising drug candidates, including CNV1014802, which is being developed for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disorder that causes the formation of bone in soft tissue. They also have several immuno-oncology candidates, including CMP-001, a toll-like receptor agonist that is being developed in conjunction with Tecentriq for the treatment of multiple types of cancer.

In addition to its pipeline, Centessa is also actively pursuing partnerships and collaborations with other companies and organizations in order to expand its reach and accelerate the development of its drug candidates. They are committed to developing innovative and effective therapies for patients in need, and they are rapidly becoming a major player in the biopharmaceutical industry.


   Company Address: 3rd Floor Cheshire 0
   Company Phone Number: 789784   Stock Exchange / Ticker: NASDAQ CNTA
   CNTA is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Centessa Pharmaceuticals Plc

Headline: Centessa Pharmaceuticals Plc Shows Promising Progress with Decreasing Operating Shortfall in Q3 2023

The Major Pharmaceutical Preparations industry has seen a wave of smaller companies making their mark on the market, with some impressive earnings to show for it. One such company, Centessa Pharmaceuticals Plc, has recently reported an operating shortfall of $-40.209 million for the third quarter of 2023. While this may seem like a setback, it is important to consider the overall progress and trajectory of the company.
Operating predominantly in the development stage, Centessa Pharmaceuticals Plc is still in the process of establishing itself in the industry. Despite the current operating shortfall, there is a positive surprise in the fact that the diminishing returns have decreased to $-38.648 million from $-53.875 million in the same period of the previous year. This improvement indicates that the company is moving in the right direction and making strides towards success.

Centessa Pharmaceuticals Plc

Centessa Pharmaceuticals Plc Narrows Operating Deficit to $-47.019 Million, Signaling Remarkable Improvement in Q2 2023 Financials

Centessa Pharmaceuticals Plc: A Promising Revelation in the Pharmaceutical Industry
The second quarter of 2023 has brought some promising news for Centessa Pharmaceuticals Plc, a leading player in the Major Pharmaceutical Preparations sector. As consultants analyze the financial numbers for April to June 30 in 2023, they observe an operating deficit of $-47.019 million, a significant improvement from the $-68.414 million deficit reported in the same period last year. This revelation has instilled confidence among countless industry analysts, who view it as a positive sign for Centessa Pharmaceuticals (CNTA).
One of the most striking aspects of this improvement is that it has occurred without any mention of top-line figures. Typically, financial performance in the pharmaceutical industry is evaluated based on both top-line and bottom-line numbers. Top-line figures reflect a company's revenue, while bottom-line figures portray its profitability. However, in this case, the operating deficit reduction has caught the attention of experts, as it suggests the company's efforts to enhance efficiency and reduce losses.

Centessa Pharmaceuticals Plc

Centessa Pharmaceuticals Plc Reports Surprising Turnaround with Operating Loss Reduction of $-48.877 Million

The earnings cycle for the fiscal period of January to March 31, 2023 has resumed, and there has been a lot of buzz surrounding the earnings announcements of various entities. Among these are numerous constituents of the major pharmaceutical preparations sector. One company, in particular, has been in the news for its reported operating loss of $-48.877 million for the first quarter of the 2023 earnings season - CNTA.
Despite the rather ominous numbers at first glance, this operating loss has been deemed a pleasant surprise by many analysts. In fact, the improvement from the operating loss for Q1 of 2022, which was $-53.218 million, has further bolstered the optimism surrounding CNTA. By running the company more cost-effectively and slashing the deficit to $-50.714 million, the executives at CNTA have demonstrated their ability to effectively manage the company's finances.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com